Transcriptional response to interferon beta-1a treatment in patients with secondary progressive multiple sclerosis

ABSTRACT: Interferon (IFN) beta-1a is an approved treatment for relapsing remitting multiple sclerosis (RRMS) and has been examined for use in secondary progressive multiple sclerosis (SPMS). However, no information regarding blood transcriptional changes induced by IFN treatment in SPMS patients is available. Our aim was to identify a subgroup of SPMS patients presenting a gene expression signature similar to that of RRMS patients who are clinical responders to IFN treatment.

ORGANISM(S): Homo sapiens

PROVIDER: GSE73608 | GEO | 2015/10/06

SECONDARY ACCESSION(S): PRJNA297802

REPOSITORIES: GEO